Representativity of TMA studies.

The smaller the portion of a tumor sample that is analyzed becomes, the higher is the risk of missing important histological or molecular features that might be present only in a subset of tumor cells. Many researchers have, therefore, suggested using larger tissue cores or multiple cores from the same donor tissue to enhance the representativity of TMA studies. However, numerous studies comparing the results of TMA studies with the findings from conventional large sections have shown that all well-established associations between molecular markers and tumor phenotype or patient prognosis can be reproduced with TMAs even if only one single 0.6 mm tissue spot is analyzed. Moreover, the TMA technology has proven to be superior to large section analysis in finding new clinically relevant associations. The high number of samples that are typically included in TMA studies, and the unprecedented degree of standardization during TMA experiments and analysis often give TMA studies an edge over traditional large-section studies.

[1]  Matthew Sydes,et al.  Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study. , 2008, The Lancet. Oncology.

[2]  R. Simon,et al.  Chromosomal aberrations associated with invasion in papillary superficial bladder cancer , 1998 .

[3]  I. Jacobs,et al.  Genetic intra‐tumour heterogeneity in epithelial ovarian cancer and its implications for molecular diagnosis of tumours , 2007, The Journal of pathology.

[4]  G. Sauter,et al.  Distinct Subcellular Expression Patterns of Neutral Endopeptidase (CD10) in Prostate Cancer Predict Diverging Clinical Courses in Surgically Treated Patients , 2008, Clinical Cancer Research.

[5]  M. J. van de Vijver,et al.  Association of C‐MYC amplification with progression from the in situ to the invasive stage in C‐MYC‐amplified breast carcinomas , 2003, The Journal of pathology.

[6]  J. Shah,et al.  Clinical significance of molecular expression profiles of Hürthle cell tumors of the thyroid gland analyzed via tissue microarrays. , 2002, The American journal of pathology.

[7]  G. Sauter,et al.  Predictive value of prostate-specific antigen expression in prostate cancer: a tissue microarray study. , 2009, Urology.

[8]  M. Salto‐Tellez,et al.  Reliability of Tissue Microarrays in Detecting Protein Expression and Gene Amplification in Breast Cancer , 2003, Modern Pathology.

[9]  D. Rimm,et al.  Validation of Tissue Microarray Technology in Breast Carcinoma , 2000, Laboratory Investigation.

[10]  Lydia Sánchez,et al.  Hodgkin and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: analyses using tissue microarrays. , 2003, Blood.

[11]  G. Sauter,et al.  Pussycats and baby tigers: non‐invasive (pTa) and minimally invasive (pT1) bladder carcinomas are not the same! , 1998, The Journal of pathology.

[12]  J. Kononen,et al.  Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.

[13]  G. Sauter,et al.  Immunological microenvironment in prostate cancer: High mast cell densities are associated with favorable tumor characteristics and good prognosis , 2009, The Prostate.

[14]  H. Moch,et al.  Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer. , 2001, Journal of the National Cancer Institute.

[15]  C. Cordon-Cardo,et al.  High Ki‐67 proliferative index predicts disease specific survival in patients with high‐risk soft tissue sarcomas , 2001, Cancer.

[16]  K. Pienta,et al.  Tissue Microarray Sampling Strategy for Prostate Cancer Biomarker Analysis , 2002, The American journal of surgical pathology.

[17]  G. Sauter,et al.  Tissue microarrays for comparing molecular features with proliferation activity in breast cancer , 2006, International journal of cancer.

[18]  H. Moch,et al.  High-throughput tissue microarray analysis to evaluate genes uncovered by cDNA microarray screening in renal cell carcinoma. , 1999, The American journal of pathology.

[19]  C. Cordon-Cardo,et al.  Validation of tissue microarrays for immunohistochemical profiling of cancer specimens using the example of human fibroblastic tumors. , 2001, The American journal of pathology.

[20]  L. Bubendorf,et al.  Expression patterns of potential therapeutic targets in prostate cancer , 2005, International journal of cancer.

[21]  S. Pileri,et al.  High‐throughput tissue microarray analysis of G1‐cyclin alterations in classical Hodgkin's lymphoma indicates overexpression of cyclin E1 , 2003, The Journal of pathology.

[22]  Holger Moch,et al.  Microarrays of bladder cancer tissue are highly representative of proliferation index and histological grade , 2001, The Journal of pathology.

[23]  Y. Chen,et al.  Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis. , 2000, Journal of the National Cancer Institute.

[24]  Gieri Cathomas,et al.  Arterial Neovascularization and Inflammation in Vulnerable Patients: Early and Late Signs of Symptomatic Atherosclerosis , 2004, Circulation.

[25]  H. Morreau,et al.  Conventional and tissue microarray immunohistochemical expression analysis of mismatch repair in hereditary colorectal tumors. , 2003, The American journal of pathology.

[26]  Mårten Fernö,et al.  Evaluation of the tissue microarray technique for immunohistochemical analysis in rectal cancer. , 2002, Archives of pathology & laboratory medicine.

[27]  C. Pilarsky,et al.  GOLPH2 protein expression as a novel tissue biomarker for prostate cancer: implications for tissue-based diagnostics , 2008, British Journal of Cancer.

[28]  A Semjonow,et al.  Cytogenetic analysis of multifocal bladder cancer supports a monoclonal origin and intraepithelial spread of tumor cells. , 2001, Cancer research.

[29]  L. Hood,et al.  WDR19 Expression is Increased in Prostate Cancer Compared with Normal Cells, but Low-Intensity Expression in Cancers is Associated with Shorter Time to Biochemical Failures and Local Recurrence , 2008, Clinical Cancer Research.

[30]  A. Haese*,et al.  Clinical significance of p53 alterations in surgically treated prostate cancers , 2008, Modern Pathology.

[31]  A. Haese*,et al.  Clinical Significance of Epidermal Growth Factor Receptor Protein Overexpression and Gene Copy Number Gains in Prostate Cancer , 2007, Clinical Cancer Research.

[32]  E. Cho,et al.  Comparison of Her-2, EGFR and Cyclin D1 in Primary Breast Cancer and Paired Metastatic Lymph Nodes: An Immunohistochemical and Chromogenic In Situ Hybridization Study , 2008, Journal of Korean medical science.

[33]  Mef Nilbert,et al.  Tissue Microarray Technique in Soft Tissue Sarcoma: Immunohistochemical Ki-67 Expression in Malignant Fibrous Histiocytoma , 2001, Applied immunohistochemistry & molecular morphology : AIMM.

[34]  J. Teruya-Feldstein,et al.  Application of tissue microarray technology to the study of non-Hodgkin's and Hodgkin's lymphoma. , 2002, Human pathology.

[35]  H. Moch,et al.  Tissue microarrays for rapid linking of molecular changes to clinical endpoints. , 2001, The American journal of pathology.